elsunersen
elsunersen: developed by 1 company · 1 clinical trial tracked.
elsunersen evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect elsunersen to PRAX; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could elsunersen → PRAX affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Epileptic Encephalopathy
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Praxis Precision Medicines, Inc. (PRAX) Epileptic Encephalopathy | Phase 3 |
Clinical Trials (1)
A Multi-Center, Single-Arm Clinical Trial to Investigate the Efficacy and Safety of Elsunersen in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy
Primary endpoint: To assess the efficacy of elsunersen on seizure frequency in participants with early-onset SCN2A DEE
Interventionalopen40 targetStarted 2025-08Completion 2028-1210 sites · Brazil, Germany, Italy, United StatesPraxis Precision Medicines
Frequently asked questions
Who is developing elsunersen?
elsunersen is being developed by Praxis Precision Medicines, Inc..
How many clinical trials involve elsunersen?
BioSniper tracks 1 clinical trial involving elsunersen.